New hope for Drug-Resistant HIV: early access to TMC125
Disease control
APPROVED_FOR_MARKETING
This study provides early access to the experimental drug TMC125 (etravirine) for HIV-1 patients who have failed multiple treatments and have few options left. Participants take TMC125 along with other antiretroviral drugs chosen by their doctor. The study tracks safety and how w…
Sponsor: Tibotec Pharmaceuticals, Ireland • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC